Status: Recruiting
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Joyce Liu, MDUpdated: Mar 2, 2026Locations: 2
Eligibility criteria
Participants must have histologically or cytologically confirmed recurrent or pe... [+17]
Participants who have had chemotherapy, radiotherapy, or investigational therapy... [+10]